Efficacy of diammonium glycyrrhizinate combined with vitamin C for treating hospitalized COVID-19 patients: a retrospective, observational study
Efficacy of diammonium glycyrrhizinate combined with vitamin C for treating hospitalized COVID-19 patients: a retrospective, observational study
复制标题
甘草酸二铵联合维生素 C 治疗住院 COVID-19 患者的疗效：一项回顾性观察性研究
DOI：
10.1093/qjmed/hcab184
复制
发表时间：
2021-10-15
影响因子：
13.3
通讯作者：
Liu, J.
中科院分区：
文献类型：
--
作者：
Tan, R.;Xiang, X.;Liu, J.
Abstract Background The current global coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has shown limited responses to medical treatments. Aims To observe the effect of combination treatment of giammonium glycyrrhizinate and vitamin C （DV）on the prognoses of patients with COVID-19. Methods This retrospective observational study recruited 207 COVID-19 patients from Tongji Hospital, patients were assigned to DV and non-DV groups on the basis of the DV treatment. To make the results more credible, a propensity-score matching (PSM) approach was adopted at a 1:3 ratio to determine the participants. Logistic analysis was used to assess the effect of DV therapy in the progress of COVID-19. Results In the DV group, the new onset incidence rate of acute respiratory distress syndrome (ARDS) after admission was clearly lower than that in the non-DV group (DV vs non-DV groups, 15.2% vs 35.7%; P = 0.002). Compared with the non-DV group, the DV group showed fewer new onset of complications (such as ARDS, acute liver injury and acute myocardial injury) (DV vs non-DV groups , 19.6% vs 46.1%; P = 0.000). Moreover, DG+VC may help to recover the count of NK cells and decrease the level of sIL-2R. Conclusions DG+VC might be a promising candidate for preventing the deterioration of COVID-19 patients, which is worthy to be studied in large and perspective cohort.
